公开(公告)号：US09682960B2

公开(公告)日：2017-06-20

申请号：US14567970

申请日：2014-12-11

申请人： Fernand Labrie ,  Shankar Mohan Singh ,  Richard Labrecque ,  Liviu Constantin Ciobanu

发明人： Fernand Labrie ,  Shankar Mohan Singh ,  Richard Labrecque ,  Liviu Constantin Ciobanu

IPC分类号： C07D401/04 ,  C07D403/12 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/506 ,  A61K31/517 ,  A61K45/06 ,  C07D401/12 ,  C07D401/14 ,  A61K38/09 ,  A61K31/58

CPC分类号： C07D403/12 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/506 ,  A61K31/517 ,  A61K31/58 ,  A61K38/09 ,  A61K45/06 ,  C07D401/12 ,  C07D401/14 ,  A61K2300/00

摘要： Compounds having the structure or their salts: are used to treat or reduce the likelihood of acquiring androgen-dependent diseases, such as prostate cancer, benign prostatic hyperplasia, polycystic ovarian syndrome, acne, hirsutism, seborrhea, androgenic alopecia, male baldness, muscle atrophy and weakness, sarcopenia, male hypogonadism, erectile dysfunction, female sexual dysfunction and osteoporosis. They can be formulated together with pharmaceutically acceptable diluent or carrier or otherwise made into any pharmaceutical dosage form. Combinations with other active pharmaceutical agents are also disclosed.

公开(公告)号：US20150175576A1

公开(公告)日：2015-06-25

申请号：US14567970

申请日：2014-12-11

申请人： Fernand LABRIE ,  Shankar Mohan SINGH ,  Richard LABRECQUE ,  Liviu Constantin CIOBANU

发明人： Fernand LABRIE ,  Shankar Mohan SINGH ,  Richard LABRECQUE ,  Liviu Constantin CIOBANU

IPC分类号： C07D403/12 ,  A61K31/4439 ,  A61K45/06 ,  A61K31/496 ,  A61K31/517 ,  A61K31/444 ,  A61K31/506 ,  A61K31/4709 ,  A61K31/4725 ,  C07D401/12 ,  C07D401/14

CPC分类号： C07D403/12 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/506 ,  A61K31/517 ,  A61K31/58 ,  A61K38/09 ,  A61K45/06 ,  C07D401/12 ,  C07D401/14 ,  A61K2300/00

摘要： Compounds having the structure or their salts: are used to treat or reduce the likelihood of acquiring androgen-dependent diseases, such as prostate cancer, benign prostatic hyperplasia, polycystic ovarian syndrome, acne, hirsutism, seborrhea, androgenic alopecia, male baldness, muscle atrophy and weakness, sarcopenia, male hypogonadism, erectile dysfunction, female sexual dysfunction and osteoporosis. They can be formulated together with pharmaceutically acceptable diluent or carrier or otherwise made into any pharmaceutical dosage form. Combinations with other active pharmaceutical agents are also disclosed.

摘要翻译： 具有结构或其盐的化合物用于治疗或降低获得雄激素依赖性疾病如前列腺癌，良性前列腺增生，多囊卵巢综合征，痤疮，多毛症，皮脂溢性，雄激素性脱发，男性秃发，肌肉萎缩的可能性 肌无力，男性性腺功能减退，勃起功能障碍，女性性功能障碍和骨质疏松症。 它们可以与药学上可接受的稀释剂或载体一起配制或以其它方式制成任何药物剂型。 还公开了与其它活性药剂的组合。